NeoGenomics is one of the designated laboratories in the NCI-MATCH trial.
What is NCI-MATCH?
The National Cancer Institute (NCI) and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) co-developed the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) study (also known as study EAY131). NCI-MATCH is a large precision medicine cancer trial with nearly 40 treatment arms exploring numerous genetic abnormalities and drugs in a large number of rare and common cancer types.
To determine whether certain drugs or drug combinations in adults whose tumors have specific genomic abnormalities will effectively treat their cancer, regardless of their cancer type.
Testing for Eligibility
Tumor gene testing by a designated lab is the only pathway for new patients to enroll into the trial. The laboratory referral process applies to eligible cancer patients who have their tumors genomically profiled by a designated laboratory at one of the nearly 1100 clinical sites across the United States. NeoGenomics is a designated laboratory for NCI-MATCH. NeoGenomics provides 19 different NeoTYPE® Solid Tumor Profiles that may qualify a patient for the study. There are two pan-tumor (broad) Profiles and 17 targeted (tumor-specific) Profiles as shown below. The NeoTYPE Discovery Profile is a common choice for clinical trial screening because it is our most comprehensive Profile, evaluating 323 genes by next-generation sequencing (NGS).
- Discovery (323 genes)
- Precision (46 genes)
- GI Predictive
- GIST & Soft Tissue
- Head & Neck
- Other Solid Tumor
Call Client Services to order a NeoTYPE Solid Tumor Profile at 866.776.5907, option 3.
Click here to request historical review of NeoTYPE Discovery Profile for potential NCI-MATCH eligibility.
NeoTYPE Cancer Profiles are Laboratory Developed Tests (LDTs) under the Clinical Laboratory Improvements Act (CLIA).
- For institutional billing questions please visit here.
- For patient billing questions please visit here.
Primary ID EAY131
Secondary IDs NCI-2015-00054
Clinicaltrials.gov ID NCT02465060